← All trials
NCT06023589
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 24, 2023
- Primary completion
- Apr 23, 2027
- Completion date
- Dec 31, 2027
- First posted
- Sep 5, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 372
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- AmgenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.